2022. Chimeric ScFv Monoclonal Antibody Composed of Tocilizumab-Light Chain, Heavy Chain, and Bacterial Flagellin for the Treatment of Autoimmune Disorder: Insilco Design and Cytotoxicity Study. Journal of Pharmaceutical Negative Results. (Nov. 2022), 644–659.